August 4, 2026, (Inside AI) — Pathos AI, a New York City-based artificial intelligence-driven drug development company, has agreed to license an experimental breast cancer drug from China’s Jiangsu Alphamab Biopharmaceutical, a subsidiary of Alphamab Oncology. The upfront payment is $125 million, with total potential deal value reaching $2.09 billion including milestone payments. The drug, JSKN016, is in late-stage trials for triple-negative breast cancer (TNBC), an aggressive cancer with limited treatment options.
Pathos AI gains exclusive rights to develop, manufacture, and commercialize JSKN016 outside Taiwan, Macau, Hong Kong, and mainland China. The deal positions Pathos AI against major pharmaceutical companies like Merck and Gilead, whose drugs Keytruda and Trodelvy are already approved for TNBC. TNBC accounts for 10% to 15% of all breast cancers and is known for rapid growth and poor prognosis.
"JSKN016 has potential to address significant unmet need across a range of solid tumors," Pathos AI CEO Iker Huerga said in a statement.
JSKN016 is a bispecific antibody designed to target both HER2 and TROP2, proteins overexpressed in many solid tumors. This dual-targeting mechanism may offer advantages over existing therapies by attacking cancer cells through two pathways simultaneously. Early clinical data presented at the 2024 American Society of Clinical Oncology (ASCO) meeting showed promising safety and efficacy signals in heavily pretreated patients, though full Phase 3 results are pending.
Pathos AI, founded in 2022 by former Tempus executives, uses machine learning to accelerate clinical trials and identify optimal patient populations. The company’s platform analyzes real-world data and genomic information to predict drug responses, potentially reducing trial failures. Licensing JSKN016 aligns with its strategy of in-licensing late-stage assets and applying AI to improve development efficiency.
Alphamab Oncology’s pipeline includes Envafolimab, a subcutaneous PD-L1 inhibitor approved in China, and Anbenitamab, a gastric cancer drug. The JSKN016 deal provides non-dilutive funding for Alphamab while retaining rights in Greater China. For Pathos AI, the agreement marks its largest transaction to date and signals ambitious expansion into oncology.
AI’s Role in Oncology Licensing Heats Up
Pathos AI’s move reflects a growing trend of AI-native biotech companies licensing clinical-stage drugs from Chinese firms. In 2025, Insilico Medicine out-licensed an AI-discovered fibrosis drug to a European pharma for $1.2 billion. These deals often involve assets validated by Chinese clinical data but lacking global commercial infrastructure, which AI companies aim to provide through data-driven development.
However, regulatory risks remain. The U.S. BIOSECURE Act, if enacted, could restrict collaborations with certain Chinese biotechs. Pathos AI’s deal with Jiangsu Alphamab, a subsidiary not currently on restricted lists, may face scrutiny if geopolitical tensions escalate. Additionally, JSKN016 must demonstrate superiority over entrenched competitors like Keytruda and Trodelvy, which generated combined sales of over $30 billion in 2025.
Pathos AI’s computational platform could be key. A 2024 paper in Nature Medicine showed that AI-driven patient stratification improved TNBC trial success rates by 40%. If Pathos AI applies similar methods to JSKN016, it might identify biomarker-defined subgroups where the drug outperforms existing therapies, a strategy that helped Gilead’s Trodelvy gain approval.
What the Deal Leaves Unanswered
Financial terms beyond the upfront payment remain undisclosed, including milestone triggers and royalty rates. Pathos AI, which raised $300 million in a 2025 Series B round, may need additional financing to fund late-stage trials and commercialization. The company has not disclosed timelines for regulatory submission or expected launch dates.
For Alphamab Oncology, the deal provides immediate capital but also transfers significant upside potential. If JSKN016 succeeds globally, Pathos AI will capture most of the value outside China. Alphamab’s Hong Kong-listed shares rose 3.2% on the news, reflecting cautious optimism.
Pathos AI’s next steps include initiating a global Phase 3 trial and building commercial infrastructure. The company may partner with larger pharmaceutical firms for co-commercialization, a common strategy for AI biotechs lacking sales forces. As the AI-driven drug development space matures, deals like this will test whether computational insights can translate into clinical and commercial success.
